Detalles de la búsqueda
1.
Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1).
J Eur Acad Dermatol Venereol
; 38(6): 1112-1120, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38279575
2.
Expert consensus on the systemic treatment of atopic dermatitis in special populations.
J Eur Acad Dermatol Venereol
; 37(6): 1135-1148, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36695072
3.
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
J Eur Acad Dermatol Venereol
; 37(10): 2047-2055, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37319109
4.
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
Br J Dermatol
; 186(3): 466-475, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34652810
5.
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.
Br J Dermatol
; 185(6): 1135-1145, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34157132
6.
Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.
J Eur Acad Dermatol Venereol
; 35(12): 2431-2439, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34378812
7.
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond.
J Eur Acad Dermatol Venereol
; 35(4): 797-806, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33533553
8.
AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
Br J Dermatol
; 182(2): 316-326, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31206593
9.
Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial.
Br J Dermatol
; 182(4): 889-899, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31286480
10.
Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab.
Br J Dermatol
; 182(1): 180-189, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30916381
11.
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
Br J Dermatol
; 182(6): 1359-1368, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31487406
12.
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies.
J Eur Acad Dermatol Venereol
; 34(12): 2809-2820, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32271970
13.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.
Br J Dermatol
; 180(6): 1352-1360, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30207587
14.
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
Br J Dermatol
; 180(5): 1039-1049, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30485400
15.
Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
J Eur Acad Dermatol Venereol
; 33(6): 1098-1106, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30838709
16.
Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies.
J Eur Acad Dermatol Venereol
; 38(7): e557-e561, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38213065
17.
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Br J Dermatol
; 179(2): 320-328, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29488226
18.
Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
Br J Dermatol
; 179(3): 615-622, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29742274
19.
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Br J Dermatol
; 178(3): 674-681, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28991370
20.
Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders.
J Eur Acad Dermatol Venereol
; 32(7): 1111-1119, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29438576